市場調查報告書
商品編碼
1403495
尿道感染市場至2030年的預測:按產品類型、治療類型、測試類型、適應症、分銷管道、最終用戶和地區的全球分析Urinary Tract Infection Market Forecasts to 2030 - Global Analysis By Product, Treatment Type, Test Type, Indication, Distribution Channel, End User and By Geography |
根據 Stratistics MRC 的資料,2023年全球尿道感染市場規模為 66 億美元,預計2030年將達到 110.7 億美元,預測期內年複合成長率為 7.67%。
尿道感染是尿液檢查,用於檢測和管理多種疾病,包括尿道感染、腎臟疾病和糖尿病。尿道感染是一種常見的疾病,主要由進入尿道並在泌尿道內繁殖的細菌所引起。該公司透過提供適合尿道結石管理的診斷工具、抗生素和治療方法,為醫療保健產業做出貢獻。
根據美國家庭醫師學會(AAFP)Leonardo Ferreira2020年 3月的報告,腎結石是一種常見疾病,每年每 1000 人中有 8 例發病。根據同一來源,大約 13%的男性和 7%的女性在一生中會患上腎結石,而美國閉尿症的總體發生率為每年每 1,000 名男性 4.5 至 6.8 例。
尿道感染(UTI)的盛行率不斷上升,特別是在女性、老年人和免疫力人群中,推動對診斷和治療方案的需求。人口老化、對尿道感染感染知識的增加以及對早期發現和及時治療的日益重視是推動尿道感染市場成長的一些因素。此外,這個市場促進因素凸顯了對新型診斷、抗生素和預防措施的需求,並鼓勵對尿道結石新產品和治療方法的開發進行投資和研究。
由於抗生素的過度使用和濫用而導致抗藥性細菌的出現,使得尿道感染的有效治療變得困難。新治療方法的需求源於這樣一個事實:這種抗藥性細菌限制了現有抗生素的有效性並使標準治療方法變得複雜。在尿道結石治療中對抗抗生素抗藥性需要重點研究和開發,以尋找新藥和替代治療方法。
照護端診斷和快速分子檢測是先進診斷工具的例子,可以幫助更快、更準確地識別尿道結石。這使得抗生素的有效使用和及時治療成為可能,在人們對抗生素抗藥性日益擔憂的情況下改善患者照護。投資尿道結石診斷解決方案的公司可以受益於對準確、高效的診斷技術日益成長的需求,改善整體醫療保健結果,並減輕泌尿結石治療的經濟負擔。
泌尿器官系統尿道結石是一種影響泌尿系統的常見細菌感染疾病,由於大眾對其原因、症狀和預防措施了解不足,常常未被發現。這種認知的缺乏阻礙了早期診斷和及時的醫療干預,導致併發症和醫療費用增加。然而,關於衛生習慣的誤解和資訊不足導致了尿道結石的流行。缺乏認知不僅會影響個人健康結果,還會對醫療保健系統造成壓力。
對管理和遏制病毒的關注已經將醫療保健資源、注意力和資金從其他醫療疾病(包括尿道結石)轉移開。封鎖、獲得醫療服務的機會有限以及患者害怕去醫療機構就診,導致診斷和治療的延誤,加劇了尿道結石的嚴重程度。此外,增加使用抗生素來治療與 COVID-19 相關的細菌感染疾病可能會導致抗生素抗藥性並限制標準尿道結石治療的有效性。供應鏈中斷也影響了尿道結石治療和診斷的可得性。
預計抗生素領域在預測期內將佔最大佔有率。在尿道感染市場的抗生素領域,有多種藥物用於治療細菌性泌尿道感染疾病。 BETA-內醯胺抗生素(例如阿莫西林)和Fluoroquinolones抗生素(例如Ciprofloxacin)是經常用於治療尿道感染的抗生素。此外,進行的研究和開發的目標是減少副作用、最大限度地減少抗藥性並提高這些抗生素的有效性。
尿道感染市場的臨床實驗室領域預計將出現盈利成長。臨床實驗室在透過分析尿液樣本來識別和確認尿道結石方面發揮著非常重要的作用,包括評估細菌的存在和確定抗生素敏感性。這些實驗室利用先進的技術和測試方法來確保準確、及時的結果並促進及時的醫療干預。此外,自動化和分子診斷技術的採用提高了尿道結石診斷的效率和準確性。
在醫療成本上升、醫療基礎設施改善以及對尿道結石認知提高的背景下,由於對診斷和治療解決方案的需求,亞太地區的尿道感染市場顯著擴大。尿道結石發生率的增加也是由於生活型態的改變和老化所造成的。此外,有利的政府措施以及製藥和醫療保健公司的成長支持該地區的成長。
在歐洲,由於老年人口的增加和社會意識的提高,尿道感染市場顯著擴大。糖尿病和尿失禁等危險因子的日益普及也推動了歐洲的成長。此外,政府提高人們對泌尿器官系統健康問題的認知並鼓勵採取預防措施的宣傳活動推動歐盟市場的成長。
According to Stratistics MRC, the Global Urinary Tract Infection Market is accounted for $6.60 billion in 2023 and is expected to reach $11.07 billion by 2030 growing at a CAGR of 7.67% during the forecast period. Urinary Tract Infections is a test of urine to detect and manage a wide range of disorders, such as urinary tract infections, kidney disease and diabetes. UTIs, caused primarily by bacteria entering the urethra and multiplying in the urinary tract, are common medical conditions. It serves the healthcare sector by providing diagnostic tools, antibiotics, and therapeutics tailored for UTI management.
According to the American Academy of Family Physicians (AAFP), in March 2020, by Leonardo Ferreira, kidney stones were a common ailment, with an annual incidence of eight instances per 1,000 persons. As per the same source, around 13% of men and 7% of women may develop a kidney stone during their lifetime, and the total incidence of urinary retention in the US is 4.5 to 6.8 per 1,000 men per year.
The increasing prevalence of urinary tract infections (UTIs), especially in women, the elderly, and people with weakened immune systems, is driving up demand for diagnostic and treatment options. The aging population, increased knowledge of UTIs, and a growing emphasis on early detection and timely treatment are some of the factors driving the UTI market's growth. Furthermore, the need for novel diagnostics, antibiotics, and preventive measures is highlighted by this market driver, which encourages investment and research in the creation of fresh goods and remedies for UTIs.
Effective treatment of urinary tract infections is becoming more difficult due to the emergence of resistant bacterial strains caused by the overuse and misuse of antibiotics. The need for new therapeutic solutions arises from the fact that this resistance limits the effectiveness of current antibiotics and complicates standard treatment regimens. In order to combat antibiotic resistance in UTI management, research and development efforts must be concentrated in order to find new medications and alternative treatment modalities.
Point-of-care diagnostics and rapid molecular testing are instances of advanced diagnostic tools that can help identify UTIs more quickly and accurately. This helps to effectively use antibiotics, addressing the growing concern of antibiotic resistance, and improves patient care by enabling timely treatment. Businesses that invest in cutting-edge UTI diagnostic solutions will profit from the growing need for accurate and efficient diagnostic techniques, which will enhance overall healthcare outcomes and lessen the financial burden of UTI treatment.
UTIs, common bacterial infections affecting the urinary system, often go undetected due to insufficient public knowledge about their causes, symptoms, and preventive measures. This dearth of awareness hampers early diagnosis and timely medical intervention, leading to complications and increased healthcare costs. However, misconceptions and inadequate information about hygiene practices contribute to the prevalence of UTIs. The lack of awareness not only affects individual health outcomes but also burdens healthcare systems.
The overwhelming focus on managing and containing the virus has diverted healthcare resources, attention, and funding away from other medical conditions, including UTIs. Lockdowns, restricted healthcare access, and patient concerns about visiting medical facilities have led to delayed diagnoses and treatments, exacerbating the severity of UTIs. Moreover, the increased use of antibiotics to treat COVID-19-related bacterial infections has contributed to antibiotic resistance, potentially limiting the effectiveness of standard UTI treatments. Supply chain disruptions have also affected the availability of UTI medications and diagnostics.
The antibiotics segment expected to have largest share over the anticipated period. A wide variety of medications are used to treat bacterial infections of the urinary tract in the Urinary Tract Infection market's antibiotics segment. Beta-lactam antibiotics, like amoxicillin, and fluoroquinolones, like ciprofloxacin, are frequently prescribed antibiotics for urinary tract infections. Additionally, the goals of ongoing research and development are to reduce side effects, minimize resistance, and improve the effectiveness of these antibiotics.
Clinical laboratories segment in the urinary tract infection market is expected to have profitable growth. Clinical laboratories are pivotal in the identification and confirmation of UTIs through the analysis of urine samples, which includes assessing bacterial presence and determining antibiotic susceptibility. These laboratories utilize advanced technologies and testing methods to ensure accurate and timely results, facilitating prompt medical intervention. Moreover, the adoption of automation and molecular diagnostic techniques within these laboratories enhances the efficiency and precision of UTI diagnostics.
The Asia-Pacific Urinary Tract Infection market is expanding substantially due to the need for diagnostic and treatment solutions is being driven by rising healthcare costs, better healthcare infrastructure, and increased awareness of UTIs. The increased frequency of UTIs is also attributed to a changing lifestyle and an aging population. Additionally, favourable government initiatives and the growth of pharmaceutical and healthcare companies are driving the regional growth.
The market for urinary tract infections is expanding substantially in Europe due to a growing geriatric population and rising public awareness. The market is growing due to risk factors like diabetes and urine incontinence are becoming more common, which is also driving growth in Europe. Additionally, government campaigns to raise awareness of urinary health issues and encourage preventative measures have been crucial in driving market growth in the European Union.
Some of the key players in Urinary Tract Infection market include Abbott Laboratories , Acon Laboratories, Inc., Allergan Plc, Arkray, Inc., Astrazeneca Plc, Bayer Ag , Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Elektronika Kft., F. Hoffmann-La Roche Ltd, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co. Inc, Mindray Medical International Limited, Novartis Ag, Pfizer Inc, Roche Diagnostics, Sanofi S.A., Siemens Healthcare, Sysmex Corporation and Urit Medical Electronic Group Co., Ltd.
In December 2023, Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies. The Agreement is based on a basic agreement on business collaboration in the field of immunoassay. Under the terms of the Agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents.
In December 2023, AstraZeneca Pharma India has entered into a Memorandum of Understanding (MoU) with Roche Diagnostics India to enhance diagnostics for breast cancer patients, particularly focusing on refining HER2 diagnostics with the latest advancements. This strategic alliance aligns with AstraZeneca's commitment to advancing patient-centric healthcare solutions and Roche Diagnostics' dedication to pioneering diagnostic innovation.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.